These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
807 related items for PubMed ID: 31221299
1. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, Kario K, Böhm M, Sharp ASP, Davies JE, Osborn JW, Fink GD, Euler DE, Cohen DL, Schlaich MP, Esler MD. JACC Cardiovasc Interv; 2019 Jun 24; 12(12):1095-1105. PubMed ID: 31221299 [Abstract] [Full Text] [Related]
3. Renal Denervation in the treatment of Resistant Hypertension. Yap LB, Balachandran K. Med J Malaysia; 2021 Nov 24; 76(6):893-897. PubMed ID: 34806679 [Abstract] [Full Text] [Related]
8. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, Mendelsohn F, Bouchard A, Larrain G, Haase M, Diaz-Cartelle J, Leon MB. JACC Cardiovasc Interv; 2020 Feb 24; 13(4):461-470. PubMed ID: 32081240 [Abstract] [Full Text] [Related]
9. A Systematic Review of Randomized Controlled Trials Comparing Renal Sympathetic Denervation Versus Sham Procedure for the Management of Uncontrolled Hypertension. Maqsood MH, Rubab K, Anwar F, Afzal Khan MT, Maqsood MA, Farooq M, Tabaza L, Rangaswami J, Virk HUH. J Cardiovasc Pharmacol; 2021 Feb 01; 77(2):153-158. PubMed ID: 33235031 [Abstract] [Full Text] [Related]
16. Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. Lauder L, Ewen S, Tzafriri AR, Edelman ER, Cremers B, Kulenthiran S, Ukena C, Linz D, Kindermann I, Tsioufis C, Scheller B, Böhm M, Mahfoud F. Cardiovasc Revasc Med; 2018 Feb 01; 19(7 Pt B):845-851. PubMed ID: 29555535 [Abstract] [Full Text] [Related]
17. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators. Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612 [Abstract] [Full Text] [Related]
18. Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. Böhm M, Townsend RR, Kario K, Kandzari D, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Hickey GL, Fahy M, DeBruin V, Brar S, Pocock S. Clin Res Cardiol; 2020 Mar 22; 109(3):289-302. PubMed ID: 32034481 [Abstract] [Full Text] [Related]
19. Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment. Wilson AL, Gandhi J, Suh Y, Joshi G, Smith NL, Khan SA. Curr Hypertens Rev; 2020 Mar 22; 16(2):115-127. PubMed ID: 30827252 [Abstract] [Full Text] [Related]
20. Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study. Gosse P, Cremer A, Kirtane AJ, Lobo MD, Saxena M, Daemen J, Wang Y, Stegbauer J, Weber MA, Abraham J, Kario K, Bangalore S, Claude L, Liu Y, Azizi M. Hypertension; 2021 Feb 22; 77(2):529-536. PubMed ID: 33356403 [Abstract] [Full Text] [Related] Page: [Next] [New Search]